Download PDF
Geburtshilfe Frauenheilkd 2006; 66(3): 284-293
DOI: 10.1055/s-2006-924019
Originalarbeit

Georg Thieme Verlag KG Stuttgart · New York

Prävalenz der Insulinresistenz in Abhängigkeit vom Körpergewicht - Bedeutung für die Primärprävention kardiovaskulärer Erkrankungen

Prevalence of Insulin Resistance in Relation to Body Weight - Importance for Primary Prevention of Cardiovascular DiseasesL. Moltz1
  • 1Klinik für Präventive Medizin, Berlin
Further Information

Publication History

Eingang Manuskript: 2.9.2005 Eingang revidiertes Manuskript: 23.2.2006

Akzeptiert: 24.2.2006

Publication Date:
20 April 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zwischen der Insulinresistenz (IR) und der Entstehung von Adipositas (A), metabolischem Syndrom (MS), Diabetes mellitus Typ II (DM) bzw. kardiovaskulären Erkrankungen (CVD) besteht ein enger, sich kontinuierlich negativ entwickelnder pathophysiologischer Zusammenhang, verbunden mit einer hohen Morbidität und Mortalität und einer weltweit epidemieartigen Zunahme der Fälle. Die IR korreliert andererseits auch unabhängig von A, MS und DM direkt mit CVD. Zur Erfassung der IR wird ein in praxi leicht durchführbarer Test benötigt. In einer Studie an 115 normgewichtigen, anscheinend gesunden Probandinnen und 555 übergewichtigen bzw. adipösen Patientinnen konnte gezeigt werden, dass durch Glukose- und Insulinbestimmungen im oralen Glukosetoleranztest (o-GTT) die IR zu 27,8 % frühzeitig (bei Normgewichtigen) und zu 91,9 % rechtzeitig (bei Übergewichtigen/Adipösen) erfasst werden kann. Die Normgrenzwerte liegen für Nüchtern-Glukose bei < 102 mg/dl und für Nüchtern-Insulin bei < 13 µU/ml. Der Nachweis/Ausschluss einer IR und damit die Primärprävention aller Folgeerkrankungen muss sehr früh einsetzen, optimal mit dem 20. Lebensjahr, mit Kontrollen alle fünf bis zehn Jahre, auch bei gesunden Normgewichtigen. Die lange Latenzphase (10 - 15 Jahre) zwischen dem Nachweis einer IR und dem Auftreten klinischer Symptome wirkt sich im Hinblick auf die Effektivität von Präventionsprogrammen günstig aus.

Abstract

Insulin resistance (IR) and the development of obesity, metabolic syndrome (MS), diabetes mellitus type II (DM) and cardiovascular diseases (CVD) are closely linked to high morbidity and mortality and an epidemic increase world wide. On the other hand IR is directly correlated with CVD, independent of obesity, MS and DM. To document IR an easily performed test method is necessary. In a study on 115 female test persons of normal weight and apparently healthy and 555 overweight/obese females, the following results were obtained using an oral tolerance test for the estimation of glucose and insulin. IR could be determined early in 27.8 % of patients of normal weight, and well-aimed in 91.9 % of patients who were overweight/obese and could be treated using primary or secondary prevention. Based on our results, it may be advisable to redefine the cut-off points for glucose (102 mg/dl) and insulin (13 µU/ml) values when screening for metabolic syndrome.

Schlüsselwörter

Insulinresistenz - oraler Glukosetoleranztest - Glukose- und Insulinbestimmung - kardiovaskuläre Erkrankungen - Primärprävention

Key words

Insulin resistance - oral tolerance test of glucose - glucose and insulin determination - cardiovascular diseases - primary prevention

Literatur

  • 1 Reaven G M. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
    CrossrefPubMedGoogle Scholar
  • 2 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.  Diabetes. 1989;  38 1165-1174
    CrossrefPubMedGoogle Scholar
  • 3 Yip J, Facchini F S, Reaven G M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease.  JCEM. 1998;  83 2773-2776
    CrossrefPubMedGoogle Scholar
  • 4 Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes.  Diabetologia. 2000;  43 148-155
    CrossrefPubMedGoogle Scholar
  • 5 Yeni-Komshian H, Carantoni M, Abbasi F, Reaven G M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers.  Diabetes Care. 2000;  23 171-175
    CrossrefPubMedGoogle Scholar
  • 6 Facchini F S, Hua N, Abbasi F, Reaven G M. Insulin resistance as a predictor of age-related diseases.  JCEM. 2001;  86 3574-3578
    PubMedGoogle Scholar
  • 7 Bergmann R N. Editorial: Insulin action and distribution of tissue blood flow.  JCEM. 2003;  88 4556-4558
    PubMedGoogle Scholar
  • 8 McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G M. Use of metabolic markers to identify overweight individuals who are insulin resistent.  Ann Intern Med. 2003;  139 802-809
    PubMedGoogle Scholar
  • 9 Reaven G M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease.  JCEM. 2003;  88 2399-2403
    PubMedGoogle Scholar
  • 10 Kronmal R A, Barzilay J I, Tracy R P, Savage P J, Orchard T J, Burke G L. The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort.  JCEM. 2004;  89 2852-2858
    PubMedGoogle Scholar
  • 11 Reaven G M. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals.  Endocrinol Metab Clin N Am. 2004;  33 283-303
    CrossrefPubMedGoogle Scholar
  • 12 Reaven G M. The insulin resistance syndrome: definition and dietary approaches to treatment.  Annu Rev Nutr. 2005;  25 17.1-17.16
    PubMedGoogle Scholar
  • 13 Despres J P, Lamarche B, Mauriege P, Bernard C, Gilles D, Sital M, Lupien P J. Hyperinsulinemia as an independent risk factor for ischemic heart disease.  NEJM. 1996;  334 952-957
    CrossrefPubMedGoogle Scholar
  • 14 Zavaroni I, Bonini P, Gasparini A L, Barilli A, Zuccarelli E, Dall'Aglio E, Delsignore R, Reaven G M. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited.  Metabolism. 1999;  48 989-994
    CrossrefPubMedGoogle Scholar
  • 15 Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna R C, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.  Diabetes. 1998;  47 1643-1649
    CrossrefPubMedGoogle Scholar
  • 16 Karelis A D, Pierre D HS, Conus F, Rabasa-Lhoret R, Poehlman E T. Metabolic and body composition factors in subgroups of obesity. What do we know?.  JCEM. 2004;  89 2569-2575
    CrossrefPubMedGoogle Scholar
  • 17 McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G M. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals.  Metabolism. 2004;  53 495-499
    CrossrefPubMedGoogle Scholar
  • 18 Alberti K GMM, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications.  Diabet Med. 1998;  15 539-553
    CrossrefPubMedGoogle Scholar
  • 19 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 20 Katz A, Nambi S S, Mather K. et al . Quantitative insulin sensitivity check index: a simple, accurate methode for assessing insulin sensitivity in humans.  JCEM. 2000;  85 2402-2410
    CrossrefPubMedGoogle Scholar
  • 21 Bergmann R N, Ader M, Huecking K, Van Citters G. Accurate assessment of β-cell function: the hyperbolic correction.  Diabetes. 2002;  51 S212-220
    CrossrefPubMedGoogle Scholar
  • 22 Quon M J. Editorial: Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity.  JCEM. 2001;  86 4615-4617
    CrossrefPubMedGoogle Scholar
  • 23 Abbassi F, Reaven G M. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans.  Metabolism. 2002;  51 235-237
    CrossrefPubMedGoogle Scholar
  • 24 Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome.  JCEM. 2004;  89 1273-1276
    CrossrefPubMedGoogle Scholar
  • 25 De Fronzo R A, Tobin J D, Andres R. Glucose clamp technique. A method for quantifying insulin secretion and resistance.  Am J Physiol. 1979;  237 E214-E223
    PubMedGoogle Scholar
  • 26 Bergmann R N, Ider Y Z, Bowden C R, Cobelli C. Quantitative estimation of insulin sensitivity.  Am J Physiol. 1979;  236 E667-E677
    PubMedGoogle Scholar
  • 27 Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen M R, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome.  Diabetes Care. 2001;  24 683-689
    CrossrefPubMedGoogle Scholar
  • 28 Bonora E, Targher G, Alberich M, Bonadonna R C, Saggiani F, Zenere M B, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity.  Diabetes Care. 2000;  23 57-63
    CrossrefPubMedGoogle Scholar
  • 29 ATP III . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III).  JAMA. 2001;  285 2486-2497
    CrossrefPubMedGoogle Scholar
  • 30 Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study.  Circulation. 2002;  105 310-315
    CrossrefPubMedGoogle Scholar
  • 31 Gutt M, Davis C L, Spitzer S B, Llabre M M, Kumar M, Czarnecki E M, Schneiderman N, Skyler J S, Marks J B. Validation of the insulin sensitivity index (ISL0, 120):comparison with other measures.  Diabetes Research and Clinical Practice. 2000;  47 177-184
    CrossrefPubMedGoogle Scholar
  • 32 Haffner S M, Miettinen H, Stern M P. The homeostasis model in the San Antonio Heart Study.  Diabetes Care. 1997;  20 1087-1092
    CrossrefPubMedGoogle Scholar
  • 33 Cree M G, Newcomer B R, Katsanos C S, Sheddield M, Chinkes D, Aarsland A, Urban R, Wolfe R R. Intramuscular and liver triglycerides are increased in the elderly.  JCEM. 2003;  89 3864-3871
    PubMedGoogle Scholar
  • 34 Ostlund R E, Staten M, Kortt W M, Schultz D J, Malley M. The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2-Cholesterol level in older adults.  NEJM. 1990;  322 29-34
    PubMedGoogle Scholar
  • 35 Laakso M. How good a marker is insulin level for insulin resistance?.  Am J Epidemol. 1993;  137 959-965
    PubMedGoogle Scholar
  • 36 Forst T, Standl E, Hohberg C, Konradt T, Schulze J, Strotmann H J, Lübbens G, Pahler S, Bachinger A, Langenfeld M, Pfützner A. IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with type 2 diabetes. Diabetes UK.  Diabetic Medicine. 2004;  21 1149-1153
    CrossrefPubMedGoogle Scholar
  • 37 Mykhänen L, Laakso M, Pyörälä K. High plasma insulin level associated with coronary heart disease in the elderly.  Am J Epidemiol. 1993;  137 1190-1202
    PubMedGoogle Scholar
  • 38 Geisthövel F. Persönliche Mitteilung. 2004
    Google Scholar
  • 39 Meier J J, Nauck M A, Schmidt W E, Gallwitz B. Diagnose einer eingeschränkten Glukosetoleranz und Diabetesprävention.  Deutsches Ärzteblatt. 2002;  23 A3182-3189
    PubMedGoogle Scholar
  • 40 Schäfer-Graf U M, Vetter K. Screening, Diagnostik und Therapie des Gestationsdiabetes.  Der Gynäkologe. 2002;  35 652-660
    PubMedGoogle Scholar
  • 41 ADA . Screening for Type 2 Diabetes.  Diabetes Care. 2004;  27 S47-S54
    PubMedGoogle Scholar
  • 42 Eckardstein v A, Schulte H, Assmann G. Risk for diabetes mellitus in middle-aged caucasian male participants of the PROCAM Study: implications for the definition of impaired fasting glucose by the American Diabetes Association.  JCEM. 2000;  85 3101-3108
    PubMedGoogle Scholar
  • 43 Couthinho M, Gerstein H C, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events.  Diabetes Care. 1999;  22 233-240
    CrossrefPubMedGoogle Scholar
  • 44 Hu F B, Stampfer M J, Haffner S M, Solomon C G, Willet W C, Manson J E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.  Diabetes Care. 2002;  25 1129-1123
    CrossrefPubMedGoogle Scholar
  • 45 Hanefeld M. Fällt der Grenzwert?.  Medical Tribune. 2001;  36 3
    PubMedGoogle Scholar
  • 46 Häring H U. Pathogenesis of type II diabetes: are there common causes for insulin resistance and secretion failure?.  Exp Clin Endocrinol Diabetes. 1999;  107 17-23
    PubMedGoogle Scholar
  • 47 Carmina E, Lobo R A. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome.  Fertil Steril. 2004;  82 661-665
    CrossrefPubMedGoogle Scholar
  • 48 Barbieri M, Rizzo M R, Manzella D, Paolisso G. Age-related insulin resistance: is it an obligatory finding? The lesson from healthy centenarians.  Diabetes Metab Res Rev. 2001;  17 19-26
    CrossrefPubMedGoogle Scholar
  • 49 Fernandez-Real J M, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome.  Endocrine Reviews. 2003;  24 279-301
    PubMedGoogle Scholar
  • 50 Erdmann E, Hanefeld M. Glitazone - eine antidiabetische Substanzklasse aus kardiologischer Sicht.  Deutsches Ärzteblatt. 2004;  101 A2954-A2961
    PubMedGoogle Scholar
  • 51 Goldstein B J, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function.  JCEM. 2004;  89 2563-2568
    CrossrefPubMedGoogle Scholar
  • 52 Choi K M, Lee K W, Kim S G, Park C G, Seo H S, Choi D J, Oh D S, Baik S H. Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus.  JCEM. 2005;  90 175-180
    PubMedGoogle Scholar
  • 53 Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M. Relationship between insulin and carotid atherosclerosis in the general population.  Stroke. 1997;  28 1147-1152
    CrossrefPubMedGoogle Scholar
  • 54 Haffner S M, Williams K, Rozek M M, Stern P. Homeostasis model assessment insulin resistance in relation to 8-years of incidence of cardiovascular diseases.  Diabetologia. 2000;  43 1080
    CrossrefPubMedGoogle Scholar
  • 55 Windler E. Die Verantwortung des Frauenarztes in der Prävention von Herz-Kreislauf-Erkrankungen.  Frauenarzt. 2004;  45 735-739
    PubMedGoogle Scholar
  • 56 Howard G, O'Leary D H, Zaccaro D, Haffner S M, Rewers M, Hamman R, Selby J V, Saad M F, Savage P, Bergmann R. Insulin sensitivity and atherosclerosis.  Circulation. 1996;  93 1809-1817
    PubMedGoogle Scholar
  • 57 Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy R P, Haffner S M. Chronic subclinical inflammation as part of the insulin resistence syndrome: The Insulin Resistence Atherosclerosis Study (IRAS).  Circulation. 2000;  102 42-47
    CrossrefPubMedGoogle Scholar
  • 58 Pyörälä M, Miettinen H, Halone P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men.  Arterioscler Thromb Vasc Bio. 2000;  20 538-544
    PubMedGoogle Scholar
  • 59 Bonora E, Targher G, Alberiche M, Bonadonna R C, Saggiani F, Zenere M B, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity.  Diabetes Care. 2000;  23 57-63
    CrossrefPubMedGoogle Scholar
  • 60 Hanley A JG, Williams K, Stern M P, Haffner S M. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease.  Diabetes Care. 2002;  25 1177-1184
    PubMedGoogle Scholar
  • 61 Matthaei S, Stumvoll M, Häring H-U. Thiazolidindione (Insulinsensitizer).  Deutsches Ärzteblatt. 2001;  98 A912-918
    PubMedGoogle Scholar
  • 62 Abbasi F, Brown B W, Lamendola C, McLaughlin T, Reaven G M. Relationship between obesity, insulin resistance, and coronary heart disease risk.  J Am Coll Cardiol. 2002;  40 937-943
    CrossrefPubMedGoogle Scholar
  • 63 Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Heaften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.  Diabetes Care. 2000;  23 295-301
    CrossrefPubMedGoogle Scholar
  • 64 Olefsky J, Farquhar J W, Reaven G M, Alto P. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects.  Diabetes. 1973;  22 507-513
    PubMedGoogle Scholar
  • 65 Norhammer A, Tenerz Ä, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus : a prospective study.  Lancet. 2002;  359 2140-2144
    CrossrefPubMedGoogle Scholar
  • 66 Zylka-Menhorn V. Viele Herzinfarktpatienten sind unerkannte Diabetiker.  Dtsch Ärzteblatt. 2004;  101 A2440-2443
    PubMedGoogle Scholar
  • 67 Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner S M, Pyörälä K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction.  Diabetes Care. 1998;  21 69-75
    PubMedGoogle Scholar
  • 68 Bartnik M, Malmberg K, Norhammer A, Tenerz A, Öhrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.  European Heart Journal. 2004;  25 1990-1997
    CrossrefPubMedGoogle Scholar
  • 69 Lenz M, Müjlhauser I. Kardiovaskuläre Risikoschätzung für eine informierte Patientenentscheidung.  Med Klinik. 2004;  99 651-661
    PubMedGoogle Scholar
  • 70 Bartnik M, Ryden L, Ferran R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Öhrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe.  European Heart Journal. 2004;  25 1880-1890
    CrossrefPubMedGoogle Scholar
  • 71 Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigas J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries.  Lancet. 2004;  364 937
    CrossrefPubMedGoogle Scholar

Prof. Dr. Lothar Moltz

Klinik für Präventive Medizin

Uhlandstraße 20 - 25

10623 Berlin

Email: lomoltz@aol.com